Key result
Pulmonary hypertension affects ~1% of the population and is managed with diuretics, CCBs, and ERAs.
This review outlines the clinical presentation, diagnostic approach, and current pharmacological management strategies for pulmonary hypertension.
Answers are grounded in this paper and cite their sources.
Supports established therapies in practice; leaves open questions on optimal sequencing and long-term outcomes.
Pulmonary hypertension is estimated to involve about 1% of the population. It presents with symptoms of exertional, breathlessness and occasional chest pain, fatigue, and pedal edema. it involves the obliteration of pulmonary micro circulation and decreased gaseous exchange leading to the classical symptoms. Routine Blood tests diagnose a failing right heart. ECG and 2D Echo show right sided hypertrophy along with signs of pulmonary hypertension. Management includes diuretics, calcium channel blockers for patients responsive to vasoreactivity test, endothelin receptor, antagonists, phosphodiesterase inhibitors, and prostacyclin analogues and receptor agonists. More research is in the pipeline to slow the progression of the disease and alter the course but concrete evidence is awaited.
No takes yet. Share an insight, caveat, or question.
Jain et al. (2025) conducted a review in Pulmonary hypertension. Pulmonary hypertension affects approximately 1% of the population and is managed with therapies including diuretics, calcium channel blockers, and endothelin receptor antagonists.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: